Current trends of sentinel lymph node biopsy for breast cancer.

Current trends of sentinel lymph node biopsy for breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Current trends of sentinel lymph node biopsy for breast cancer. Abstract Text:

Hiroyuki Takei,Masafumi Kurosumi,Takashi Yoshida,Jun Ninomiya,Yasutaka Hagiwara,Mari Kamimura,Yuji Hayashi,Katsunori Tozuka,Kimito Suemasu,Kenichi Inoue,Toshio Tabei,Hiroyuki Takei,Masafumi Kurosumi,Takashi Yoshida,Jun Ninomiya,Yasutaka Hagiwara,Mari Kamimura,Yuji Hayashi,Katsunori Tozuka,Kimito Suemasu,Kenichi Inoue,Toshio Tabei,Hiroyuki Takei,Masafumi Kurosumi,Takashi Yoshida,Jun Ninomiya,Yasutaka Hagiwara,Mari Kamimura,Yuji Hayashi,Katsunori Tozuka,Kimito Suemasu,Kenichi Inoue,Toshio Tabei,

Sentinel lymph node biopsy (SLNB) is standard care for patients with early-stage breast cancer, and axillary lymph node dissection (ALND) is considered unnecessary when sentinel lymph nodes (SLNs) are tumor-free. Additional non-SLN metastasis in patients with positive SLNs can be estimated using several risk factors such as primary tumor size, metastatic tumor size in SLNs, lymphatic vessel invasion, and so on. All patients with positive SLNs may be treated with further ALND based on their own risk for non-SLN metastasis. Recent randomized clinical trials have already proved less surgical morbidity and better QOL for SLNB alone compared with ALND. However, trials concerning the efficacy of ALND in positive SLNB patients in preventing local regional recurrence and improving overall survival compared with no ALND, and also, concerning the effectiveness of ALND compared with axillary radiation therapy (RT), have not yielded clear results. The prognostic significance of micrometastasis in SLNs or bone marrow also remains to be determined. So far SLNB is not acceptable for patients with positive nodes in the axilla at initial diagnosis even if their axillary metastases are down-staged to negative by neoadjuvant chemotherapy. Although basically SLNB does not need to be performed for patients with pure ductal carcinoma in situ (DCIS), it is recommended for patients with an initial diagnosis of DCIS which is large, palpable, high grade, or found in younger patients. Because these types of DCIS have higher incidences of accompanying invasive lesions. In addition if patients will undergo mastectomy, SLNB is recommended because of the inability to perform SLNB after mastectomy. SLNB may be acceptable for patients with T3 or T4b tumors, even though SLN identification is lower yet SLN involvement is higher compared with T1 or T2 tumors, and systemic adjuvant therapy is more important for patients with T3 or T4b tumors. SLNB is a bridge to further axillary treatment such as ALND or axillary RT, and which strategy, including no further treatment, is best considered individually based on recurrence risk, treatment responsiveness and use or non-use of systemic therapy.

Current trends of sentinel lymph node biopsy for breast cancer. Publishing Authors By Initials

H Takei,M Kurosumi,T Yoshida,J Ninomiya,Y Hagiwara,M Kamimura,Y Hayashi,K Tozuka,K Suemasu,K Inoue,T Tabei,H Takei,M Kurosumi,T Yoshida,J Ninomiya,Y Hagiwara,M Kamimura,Y Hayashi,K Tozuka,K Suemasu,K Inoue,T Tabei,H Takei,M Kurosumi,T Yoshida,J Ninomiya,Y Hagiwara,M Kamimura,Y Hayashi,K Tozuka,K Suemasu,K Inoue,T Tabei,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Current trends of sentinel lymph node biopsy for breast cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Breast cancer (Tokyo, Japan)

VOLUME: 14

Page Numbers: 362-70

Journal Abbreviation: Breast Cancer

ISSN: 1340-6868

DAY: 7

MONTH: 11

YEAR: 2007

Current trends of sentinel lymph node biopsy for breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100888201

Current trends of sentinel lymph node biopsy for breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Current trends of sentinel lymph node biopsy for breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Current trends of sentinel lymph node biopsy for breast cancer.

AFFILIATION: Division of Breast Surgery, Saitama Cancer Center.

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Breast Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Current trends of sentinel lymph node biopsy for breast cancer Related Publications

• CT demonstration of sarcoidosis of the optic nerve, frontal lobes, and falx cerebri: case report and literature review.
• Current trends of sentinel lymph node biopsy for breast cancer.
• Efficient production of genetically engineered, male-sterile Arabidopsis thaliana using anther-specific promoters and genes derived from Brassica oleracea and B. rapa.
• Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03).
• Simple procedures for purification and stabilization of human serum paraoxonase-1.
• [Water electrolyte metabolism]